Cargando…

Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau)

Pathological tau aggregates in Alzheimer’s disease (AD) and frontotemporal lobar degeneration-tau (FTLD-tau) adopt distinct conformations differentiated by the AD-tau specific monoclonal antibody (mAb) GT-38 that are not readily visualized using phosphorylation-specific anti-tau mAbs. To determine t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibbons, Garrett S., Kim, Soo-Jung, Robinson, John L., Changolkar, Lakshmi, Irwin, David J., Shaw, Leslie M., Lee, Virginia M.-Y., Trojanowski, John Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399892/
https://www.ncbi.nlm.nih.gov/pubmed/30832741
http://dx.doi.org/10.1186/s40478-019-0687-5
_version_ 1783399834347110400
author Gibbons, Garrett S.
Kim, Soo-Jung
Robinson, John L.
Changolkar, Lakshmi
Irwin, David J.
Shaw, Leslie M.
Lee, Virginia M.-Y.
Trojanowski, John Q.
author_facet Gibbons, Garrett S.
Kim, Soo-Jung
Robinson, John L.
Changolkar, Lakshmi
Irwin, David J.
Shaw, Leslie M.
Lee, Virginia M.-Y.
Trojanowski, John Q.
author_sort Gibbons, Garrett S.
collection PubMed
description Pathological tau aggregates in Alzheimer’s disease (AD) and frontotemporal lobar degeneration-tau (FTLD-tau) adopt distinct conformations differentiated by the AD-tau specific monoclonal antibody (mAb) GT-38 that are not readily visualized using phosphorylation-specific anti-tau mAbs. To determine the extent of co-morbid AD-tau pathology in FTLD-tau, we performed immunohistochemical (IHC) staining with GT-38 and assigned Braak stages of AD-tau in a cohort 180 FTLD-tau cases consisting of corticobasal degeneration (CBD; n = 49), progressive supranuclear palsy (PSP; n = 109), and Pick’s disease (PiD; n = 22). Nearly two-thirds of patients (n = 115 of 180, 63.8%) with FTLD-tau had some degree of comorbid AD-tau pathology and 20.5% of the FTLD-tau cohort had Braak stage ≥B2, consistent with medium-to-high-level AD neuropathological change (ADNPC). The PSP group had the highest frequency of medium-high AD-tau pathology compared to other tauopathies (PSP = 31/109, 28.4%; Picks = 2/22, 9.1%, CBD = 4/49, 8.2%) but neuropathological diagnosis was not found to be a significant independent predictor of medium-high AD Braak stage in a multivariate model after accounting for age at death (OR = 1.09; 95% CI = 1.03–1.15; p = 0.002) and CERAD plaque scores (OR = 3.75, 95% CI = 1.58–8.89; p = 0.003), suggesting there is no predilection for a specific FTLD tauopathy to develop AD-tau co-pathology after accounting for age. Patients with FTLD-tau who had, clinically significant, medium-high AD-tau pathology had significantly higher antemortem CSF levels of both total-tau (t-tau; mean = 89.98 pg/ml, SD = 36.70 pg/ml) and phosphorylated-tau (p-tau; mean = 20.45 pg/ml, SD = 9.31 pg/ml) compared to patients with negligible-low AD-tau, t-tau (mean = 43.04 pg/ml, SD = 25.40 pg/ml) and p-tau (mean = 11.90 pg/ml, SD = 4.48 pg/ml) (p ≤ 0.001 both). Finally, in an exploratory analysis in our largest pathology group (PSP) we find an association of GT-38 AD-tau Braak stage with lower baseline MMSE (p = 0.03). Together, these finding validate the use of GT-38 to selectively detect AD-tau pathology in the context of FTLD-tau and provides a novel tool to investigate associations of clinical phenotypes amongst co-morbid tauopathies.
format Online
Article
Text
id pubmed-6399892
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63998922019-03-13 Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau) Gibbons, Garrett S. Kim, Soo-Jung Robinson, John L. Changolkar, Lakshmi Irwin, David J. Shaw, Leslie M. Lee, Virginia M.-Y. Trojanowski, John Q. Acta Neuropathol Commun Research Pathological tau aggregates in Alzheimer’s disease (AD) and frontotemporal lobar degeneration-tau (FTLD-tau) adopt distinct conformations differentiated by the AD-tau specific monoclonal antibody (mAb) GT-38 that are not readily visualized using phosphorylation-specific anti-tau mAbs. To determine the extent of co-morbid AD-tau pathology in FTLD-tau, we performed immunohistochemical (IHC) staining with GT-38 and assigned Braak stages of AD-tau in a cohort 180 FTLD-tau cases consisting of corticobasal degeneration (CBD; n = 49), progressive supranuclear palsy (PSP; n = 109), and Pick’s disease (PiD; n = 22). Nearly two-thirds of patients (n = 115 of 180, 63.8%) with FTLD-tau had some degree of comorbid AD-tau pathology and 20.5% of the FTLD-tau cohort had Braak stage ≥B2, consistent with medium-to-high-level AD neuropathological change (ADNPC). The PSP group had the highest frequency of medium-high AD-tau pathology compared to other tauopathies (PSP = 31/109, 28.4%; Picks = 2/22, 9.1%, CBD = 4/49, 8.2%) but neuropathological diagnosis was not found to be a significant independent predictor of medium-high AD Braak stage in a multivariate model after accounting for age at death (OR = 1.09; 95% CI = 1.03–1.15; p = 0.002) and CERAD plaque scores (OR = 3.75, 95% CI = 1.58–8.89; p = 0.003), suggesting there is no predilection for a specific FTLD tauopathy to develop AD-tau co-pathology after accounting for age. Patients with FTLD-tau who had, clinically significant, medium-high AD-tau pathology had significantly higher antemortem CSF levels of both total-tau (t-tau; mean = 89.98 pg/ml, SD = 36.70 pg/ml) and phosphorylated-tau (p-tau; mean = 20.45 pg/ml, SD = 9.31 pg/ml) compared to patients with negligible-low AD-tau, t-tau (mean = 43.04 pg/ml, SD = 25.40 pg/ml) and p-tau (mean = 11.90 pg/ml, SD = 4.48 pg/ml) (p ≤ 0.001 both). Finally, in an exploratory analysis in our largest pathology group (PSP) we find an association of GT-38 AD-tau Braak stage with lower baseline MMSE (p = 0.03). Together, these finding validate the use of GT-38 to selectively detect AD-tau pathology in the context of FTLD-tau and provides a novel tool to investigate associations of clinical phenotypes amongst co-morbid tauopathies. BioMed Central 2019-03-04 /pmc/articles/PMC6399892/ /pubmed/30832741 http://dx.doi.org/10.1186/s40478-019-0687-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Gibbons, Garrett S.
Kim, Soo-Jung
Robinson, John L.
Changolkar, Lakshmi
Irwin, David J.
Shaw, Leslie M.
Lee, Virginia M.-Y.
Trojanowski, John Q.
Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau)
title Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau)
title_full Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau)
title_fullStr Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau)
title_full_unstemmed Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau)
title_short Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau)
title_sort detection of alzheimer’s disease (ad) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (ftld-tau)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399892/
https://www.ncbi.nlm.nih.gov/pubmed/30832741
http://dx.doi.org/10.1186/s40478-019-0687-5
work_keys_str_mv AT gibbonsgarretts detectionofalzheimersdiseaseadspecifictaupathologywithconformationselectiveantitaumonoclonalantibodyincomorbidfrontotemporallobardegenerationtauftldtau
AT kimsoojung detectionofalzheimersdiseaseadspecifictaupathologywithconformationselectiveantitaumonoclonalantibodyincomorbidfrontotemporallobardegenerationtauftldtau
AT robinsonjohnl detectionofalzheimersdiseaseadspecifictaupathologywithconformationselectiveantitaumonoclonalantibodyincomorbidfrontotemporallobardegenerationtauftldtau
AT changolkarlakshmi detectionofalzheimersdiseaseadspecifictaupathologywithconformationselectiveantitaumonoclonalantibodyincomorbidfrontotemporallobardegenerationtauftldtau
AT irwindavidj detectionofalzheimersdiseaseadspecifictaupathologywithconformationselectiveantitaumonoclonalantibodyincomorbidfrontotemporallobardegenerationtauftldtau
AT shawlesliem detectionofalzheimersdiseaseadspecifictaupathologywithconformationselectiveantitaumonoclonalantibodyincomorbidfrontotemporallobardegenerationtauftldtau
AT leevirginiamy detectionofalzheimersdiseaseadspecifictaupathologywithconformationselectiveantitaumonoclonalantibodyincomorbidfrontotemporallobardegenerationtauftldtau
AT trojanowskijohnq detectionofalzheimersdiseaseadspecifictaupathologywithconformationselectiveantitaumonoclonalantibodyincomorbidfrontotemporallobardegenerationtauftldtau